QIAGEN NV

## QIAGEN: Five Years of Transition and Repricing

2021: Pandemic Peak and the "More Than COVID" Narrative

QIAGEN delivered pandemic-year results that looked exceptional on the surface—net sales around $2.25bn, adjusted EPS near $2.65—but the company made a deliberate point of demonstrating that non-COVID product sales had grown 22% in constant-exchange-rate terms. The market bought the story: here was a diagnostics compounder that had benefited from the pandemic but wasn't hostage to it. The stock moved higher through the year on momentum and multiple expansion, with each quarterly beat and upgraded outlook feeding the uptrend into late 2021, before the first whispers of COVID normalization began to surface.

2022: The Reckoning

The transition was real and material. Full-year net sales fell to roughly $2.14bn (flat in constant-exchange-rate terms after reported declines), while COVID-testing revenues essentially evaporated. Non-COVID product groups did grow around 14% in constant-exchange-rate terms, and operating and free cash flow remained robust at $715m and $586m respectively, but the narrative had shifted entirely. Investors stopped seeing a pandemic beneficiary and started seeing a company that needed to prove its base business could sustain growth. The stock repriced accordingly—higher volatility, material sell-offs, and a multi-quarter consolidation as the market digested what a normalized QIAGEN actually looked like.

2023: Portfolio Transformation

The company acquired Verogen (forensics and NGS capabilities) for approximately $150m and began exploring minority-stake options in its bioinformatics arm. Full-year sales landed near $1.97bn with non-COVID growth continuing at roughly 8% in constant-exchange-rate terms, and Q4 beat expectations. The narrative evolved again: this wasn't just a COVID roll-off story anymore, but a deliberate portfolio transformation around five growth pillars—sample technology, syndromic testing, digital PCR, bioinformatics, and QuantiFERON. The stock traded largely range-bound through 2023 as investors waited for proof that organic growth could actually materialize. The Verogen acquisition would later draw regulatory and legal scrutiny over GEDmatch data handling, but that friction remained isolated.

2024: Execution and Discipline

QIAGEN focused on margin expansion and shareholder returns. The company reported product milestones (expanded QIAstat-Dx menu, QIAcuity placements, QuantiFERON momentum), decided to phase out NeuMoDx by mid-2025, improved adjusted margins, generated strong free cash flow around $506m, and commenced sizeable share repurchases. The market narrative shifted toward operational discipline and cash returns—QIAGEN was increasingly viewed as an execution-oriented diagnostics compounder that returned capital to shareholders. Price action became more news-driven around earnings beats, FDA clearances, and buyback announcements, with periodic breakouts offset by volatility around legal headlines and strategic decisions.

2025: Governance Transition

Stephen H. Rusckowski was announced to succeed Lawrence Rosen as Supervisory Board chair after the June AGM, and a CEO succession process began with Thierry Bernard signaling his intention to step down once a successor was appointed. The company continued aggressive capital returns and reiterated 2028 mid-term targets. Investors interpreted the board and CEO changes as value-unlocking and governance refresh, though the leadership transition also introduced execution risk. The stock remained broadly range-bound through the year, with episodic rallies tied to buybacks and quarterly beats but no sustained breakout.

2026: Takeover Speculation and Retracement

In January 2026, reports surfaced that QIAGEN was assessing strategic options and had held talks with potential buyers. The stock rallied sharply—spiking into the low $50s on the takeover speculation—before the narrative faded as discussions remained preliminary and no firm bid materialized. Sentiment reverted toward fundamentals and the cash-return story. The takeover premium unwound over subsequent months, and by July 7, 2026, the stock had retraced to 33.7685, erasing the January spike and trading back near mid-range levels. The brief episode illustrated how thin the line can be between a genuine strategic catalyst and momentum noise—and how quickly the market reprices when the former fails to materialize.